Epirubicin hydrochloride
  • Approved Drug Name
    Epirubicin hydrochloride
  • CAS NO.
  • Quality Standard
    Enterprise Standard
  • Packaging
    10G/Bag, 20G/Bag
  • Storage Condition
    Shading,Sealing,storage temperature(2~8℃)
  • Certification
    Ongoing registration

Epirubicin hydrochloride(casno.56390-09-1) is an anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Epirubicin hydrochloride(casno.56390-09-1) is approved to be used with other drugs to treat:
Breast cancer. It is used after surgery in patients with early-stage breast cancer that has spread to the lymph nodes under the arm.
Epirubicin hydrochloride(casno.56390-09-1) is also being studied in the treatment of other types of cancer.
More About Epirubicin hydrochloride(casno.56390-09-1):
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Epirubicin hydrochloride(casno.56390-09-1) - A lay language summary of important information about this drug that may include the following:
Warnings about Epirubicin hydrochloride(casno.56390-09-1).
What does Epirubicin hydrochloride(casno.56390-09-1) used for and how it is used.
What you should tell your doctor before using Epirubicin hydrochloride(casno.56390-09-1).
What you should know about Epirubicin hydrochloride(casno.56390-09-1) before using it.
Other drugs that may interact with Epirubicin hydrochloride(casno.56390-09-1), and possible side effects.
Epirubicin hydrochloride(casno.56390-09-1) biological activity:
Antibiotic antitumor agent. Inhibits the synthesis and function of DNA (IC50 = 62.7 μM in rat glioblastoma cell lines) and inhibits the relaxing property of topoisomerase II.
Epirubicin hydrochloride(casno.56390-09-1) Computed Descriptors:
Epirubicin hydrochloride(casno.56390-09-1) IUPAC Name:
Epirubicin hydrochloride(casno.56390-09-1) InChI Name:
Epirubicin hydrochloride(casno.56390-09-1) InChI Key:
Epirubicin hydrochloride(casno.56390-09-1) Canonical SMILES:
Epirubicin hydrochloride(casno.56390-09-1) Isomeric SMILES:
Epirubicin Usage: For Research Use Only! Not For Use in Humans. The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis. All Tocris products are intended for laboratory research use only.
Epirubicin hydrochloride(casno.56390-09-1) Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Epirubicin hydrochloride(casno.56390-09-1) Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Epirubicin hydrochloride(casno.56390-09-1) Solubility: Soluble in DMSO, not in water
Epirubicin hydrochloride(casno.56390-09-1) Shelf Life: >2 years if stored properly
Epirubicin hydrochloride(casno.56390-09-1) Drug Formulation: This drug may be formulated in DMSO
Epirubicin hydrochloride(casno.56390-09-1) Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Additional Information of Epirubicin hydrochloride(casno.56390-09-1):
Drug Description of Epirubicin hydrochloride(casno.56390-09-1):
ELLENCE Injection (Epirubicin hydrochloride(casno.56390-09-1) injection) is an anthracycline cytotoxic agent, intended for intravenous administration. ELLENCE is supplied as a sterile, clear, red solution and is available in polypropylene vials containing 50 and 200 mg of Epirubicin hydrochloride(casno.56390-09-1) as a preservative-free, ready-to-use solution. Each milliliter of solution contains 2 mg of Epirubicin hydrochloride(casno.56390-09-1). Inactive ingredients include sodium chloride, USP, and water for injection, USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid, NF. Epirubicin hydrochloride(casno.56390-09-1) is the 4-epimer of doxorubicin and is a semi-synthetic derivative of daunorubicin. The chemical name is (8S- cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride. The active ingredient is a red-orange hygroscopic powder, with the empirical formula C27 H29 NO11 HCl and a molecular weight of 579.95.
Epirubicin hydrochloride Quality
Epirubicin hydrochloride Manufacturers
Epirubicin hydrochloride Suppliers
Epirubicin hydrochloride FDA
Epirubicin hydrochloride USP.EP
Epirubicin hydrochloride GMP
Epirubicin hydrochloride price
Epirubicin hydrochloride samples
Clinical Pharmacilogy of Epirubicin hydrochloride(casno.56390-09-1):
Epirubicin is an anthracycline cytotoxic agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals. The antiproliferative and cytotoxic activity of epirubicin is thought to result from these or other possible mechanisms. Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors. It is also active in vivo against a variety of murine tumors and human xenografts in athymic mice, including breast tumors.
Development History of Epirubicin hydrochloride(casno.56390-09-1):
The first trial of epirubicin in humans was published in 1980. Upjohn applied for approval by the U.S. Food and Drug Administration (FDA) in node-positive breast cancer in 1984, but was turned down because of lack of data. It appears to have been licensed for use in Europe from around this time however. In 1999 Pharmacia (who had by then merged with Upjohn) received FDA approval for the use of epirubicin as a component of adjuvant therapy in node-positive patients.